Literature DB >> 17133551

Norovirus capsid protein expressed in yeast forms virus-like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts.

Ming Xia1, Tibor Farkas, Xi Jiang.   

Abstract

Norovirus (NV) gastroenteritis is a widespread disease affecting people of all ages worldwide. A simple, safe, and easily deliverable vaccine may be the key for the control and prevention of NV gastroenteritis. In this study, we demonstrated that a NV recombinant capsid protein (strain VA387, genogroup II.4) expressed in yeast (Pichia pastoris) spontaneously formed virus-like particles (VLPs) like those expressed in other in vitro systems. Oral administration of raw material from the yeast cell lysates containing 0.1 mg of VLPs without an adjuvant resulted in systemic and mucosal immune responses in mice. Significantly higher and earlier responses were observed in mice receiving a higher dose (1 mg per dose) of the antigen. Both the serum and fecal antibodies blocked VA387 VLP binding to its histo-blood group antigen receptors. The animals did not reveal any side effect following the administration of the yeast lysates. Our results indicated that yeast is a simple, effective alternative for NV VLP production. The mice immunization study also indicated that the oral administration of raw yeast extracts without an adjuvant is a safe and simple way which is worth to be studied for vaccine delivery in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17133551     DOI: 10.1002/jmv.20762

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  17 in total

1.  A candidate dual vaccine against influenza and noroviruses.

Authors:  Ming Xia; Ming Tan; Chao Wei; Weiming Zhong; Leyi Wang; Monica McNeal; Xi Jiang
Journal:  Vaccine       Date:  2011-08-11       Impact factor: 3.641

2.  Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age.

Authors:  Tammy Bui; Jacob Kocher; Yanru Li; Ke Wen; Guohua Li; Fangning Liu; Xingdong Yang; Tanya LeRoith; Ming Tan; Ming Xia; Weiming Zhong; Xi Jiang; Lijuan Yuan
Journal:  J Gen Virol       Date:  2013-06-26       Impact factor: 3.891

Review 3.  Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.

Authors:  Ming Tan; Xi Jiang
Journal:  Nanomedicine (Lond)       Date:  2012-06       Impact factor: 5.307

Review 4.  Vaccine against norovirus.

Authors:  Ming Tan; Xi Jiang
Journal:  Hum Vaccin Immunother       Date:  2014-05-05       Impact factor: 3.452

Review 5.  Prospects and Challenges in the Development of a Norovirus Vaccine.

Authors:  Nicolas W Cortes-Penfield; Sasirekha Ramani; Mary K Estes; Robert L Atmar
Journal:  Clin Ther       Date:  2017-07-26       Impact factor: 3.393

6.  Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus.

Authors:  Yuanmei Ma; Jianrong Li
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

7.  Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

Authors:  Anna D LoBue; Joseph M Thompson; Lisa Lindesmith; Robert E Johnston; Ralph S Baric
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

8.  Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector.

Authors:  Yuanmei Ma; Yue Duan; Yongwei Wei; Xueya Liang; Stefan Niewiesk; Michael Oglesbee; Jianrong Li
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

9.  Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives.

Authors:  Jacob Kocher; Lijuan Yuan
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

Review 10.  Contribution of yeast models to virus research.

Authors:  R Sahaya Glingston; Jyoti Yadav; Jitika Rajpoot; Neha Joshi; Shirisha Nagotu
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-04       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.